File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion

TitleTargeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion
Authors
Issue Date2013
Citation
Molecular Therapy, 2013, v. 21, n. 1, p. 78-90 How to Cite?
AbstractOvarian cancer has a clear predilection to metastasize to the peritoneum, which represents one of the most important prognostic factors of poor clinical outcome. Gonadotropin-releasing hormone (GnRH) receptor is significantly overexpressed during the malignant progression of human ovarian cancer. Here, using lentiviral-based small interfering RNA (siRNA) technology to downregulate GnRH receptor in metastatic ovarian cancer cells, we show that GnRH receptor is an important mediator of ovarian cancer peritoneal metastasis. GnRH receptor downregulation dramatically attenuated their adhesion to the peritoneal mesothelium. By inhibiting the expression of GnRH receptor, we showed decreased expression of α2β1 and α5β1 integrin and adhesion to specific extracellular matrix (ECM) proteins. This was also associated with a reduction of P-cadherin. Furthermore, adhesion of ovarian cancer cells to different ECMs and the mesothelium were abrogated in response to β1 integrin and P-cadherin reduction, confirming that the effects were β1 integrin-and P-cadherin-specific. Using a mouse model of human ovarian cancer metastasis, we found that the inhibition of GnRH receptor, β1 integrin, and P-cadherin significantly attenuated tumor growth, ascites formation, and the number of metastatic implants. These results define a new role for GnRH receptor in early metastasis and offer the possibility of novel therapeutic targets. © The American Society of Gene & Cell Therapy.
Persistent Identifierhttp://hdl.handle.net/10722/225051
ISSN
2015 Impact Factor: 6.938
2015 SCImago Journal Rankings: 3.374
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, Lydia Wt-
dc.contributor.authorYung, Susan-
dc.contributor.authorChan, Tak Mao-
dc.contributor.authorLeung, Peter Ck-
dc.contributor.authorWong, Alice St-
dc.date.accessioned2016-04-18T11:16:37Z-
dc.date.available2016-04-18T11:16:37Z-
dc.date.issued2013-
dc.identifier.citationMolecular Therapy, 2013, v. 21, n. 1, p. 78-90-
dc.identifier.issn1525-0016-
dc.identifier.urihttp://hdl.handle.net/10722/225051-
dc.description.abstractOvarian cancer has a clear predilection to metastasize to the peritoneum, which represents one of the most important prognostic factors of poor clinical outcome. Gonadotropin-releasing hormone (GnRH) receptor is significantly overexpressed during the malignant progression of human ovarian cancer. Here, using lentiviral-based small interfering RNA (siRNA) technology to downregulate GnRH receptor in metastatic ovarian cancer cells, we show that GnRH receptor is an important mediator of ovarian cancer peritoneal metastasis. GnRH receptor downregulation dramatically attenuated their adhesion to the peritoneal mesothelium. By inhibiting the expression of GnRH receptor, we showed decreased expression of α2β1 and α5β1 integrin and adhesion to specific extracellular matrix (ECM) proteins. This was also associated with a reduction of P-cadherin. Furthermore, adhesion of ovarian cancer cells to different ECMs and the mesothelium were abrogated in response to β1 integrin and P-cadherin reduction, confirming that the effects were β1 integrin-and P-cadherin-specific. Using a mouse model of human ovarian cancer metastasis, we found that the inhibition of GnRH receptor, β1 integrin, and P-cadherin significantly attenuated tumor growth, ascites formation, and the number of metastatic implants. These results define a new role for GnRH receptor in early metastasis and offer the possibility of novel therapeutic targets. © The American Society of Gene & Cell Therapy.-
dc.languageeng-
dc.relation.ispartofMolecular Therapy-
dc.titleTargeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1038/mt.2012.187-
dc.identifier.pmid23164934-
dc.identifier.scopuseid_2-s2.0-84871923792-
dc.identifier.hkuros218368-
dc.identifier.volume21-
dc.identifier.issue1-
dc.identifier.spage78-
dc.identifier.epage90-
dc.identifier.eissn1525-0024-
dc.identifier.isiWOS:000313035000010-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats